A research team, which includes several members of the London Sarcoma Service, was the first to identify a genetic mutation present in approximately half of central chondrosarcomas (the second most common primary bone cancer). The breakthrough research, lead by Professor Adrienne M Flanagan, offers the potential for the development of personalised treatment for patients with tumours harbouring this mutation.

The researchers won the Jeremy Jass Prize for Research Excellence in Pathology for their paper IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

The prize was awarded in Utrecht, Netherlands, at the winter meeting of the Pathological Society of Great Britain and Ireland on 6 January 2013 and was accepted on behalf of the team by Dr Fernanda Amary.

For more information about the Jeremy Jass Prize for Research Excellence in Pathology: http://onlinelibrary.wiley.com/doi/10.1002/path.4091/abstract

< Back